Vectron Biosolutions
Vectron Biosolutions develops tailor-made E. coli protein production strains for pharmaceutical, food technology, and industrial enzyme clients, using its proprietary VB Expression, VB Evolution, and VB Secretion technology platforms under a fee-for-service and licensing model.
- Company typePrivate
- Founded2008
- HeadquartersTrondheim, Norway
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Vectron Biosolutions does
Vectron Biosolutions AS, founded in 2008 and headquartered in Trondheim, Norway, is a privately held biotechnology company that commercializes proprietary vector technologies developed at the Norwegian University of Science and Technology (NTNU). The company engineers tailor-made microbial production strains in E. coli for clients in the pharmaceutical, food technology, and industrial enzyme sectors. Its offering is anchored on three complementary technology platforms: VB Expression (a modular vector platform combining proprietary promoters, signal peptides, fusion partners, and copy number regulators around a tunable xylS/Pm expression system), VB Evolution (a directed evolution pipeline with ultra-high-throughput screening capable of generating millions of randomized vectors to identify optimal configurations), and VB Secretion (a proprietary secretion platform acquired from T3S Technologies in 2021 that uses engineered flagella to export proteins extracellularly, reducing downstream processing burden). Supporting components include CYT Tags (N-terminal cytoplasmic fusion partners), signal peptide libraries for Sec and Tat pathways, and the granted Dual UTR synthetic 5'-UTR patent.
The company operates a fee-for-service strain development model structured around five work packages (feasibility study, genetic optimization, cultivation optimization, fed-batch optimization, and research cell bank delivery), with multi-year contracts, project-based engagement, and willingness to structure profit- or risk-sharing arrangements. On project completion, strains are transferred to customers under license agreements that may include patent applications covering the customer's specific production strain, providing the customer with extended IP insulation. The company also generates revenue through technology and patent licensing. Headcount is in the 11-50 range, focused primarily on scientific staff. Distribution is a mix of direct enterprise sales (targeting pharma, CMOs, and industrial enzyme manufacturers) and channel partners including Sartorius Korea Biotech Co. (exclusive agent for the Republic of Korea since April 2022) and Cytovance Biologics (North American CDMO partner since October 2023).
Vectron Biosolutions firmographics
Firmographics- Name
- Vectron Biosolutions
- Legal name
- Vectron Biosolutions AS
- Website
- https://vectronbiosolutions.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Vectron Biosolutions develops tailor-made E. coli protein production strains for pharmaceutical, food technology, and industrial enzyme clients, using its proprietary VB Expression, VB Evolution, and VB Secretion technology platforms under a fee-for-service and licensing model.
- Ownership category
- akta.pro rank
Vectron Biosolutions industry classification
Industry- Product category
- Microbial protein production services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling) (HLAAAJAF)
- akta.pro secondary industries
- Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Process Development & Tech Transfer (Upstream/Downstream/MSAT) (HLAGAGAE)
Keywords
Where Vectron Biosolutions is headquartered
LocationHeadquarters
- HQ city
- Trondheim
- HQ country
- Norway
- HQ region
- Europe
Offices1 record
Markets served
Vectron Biosolutions business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D
Revenue model
- Strain Development Services: Fee-for-service based strain development projects with up to 5 work packages. Projects include feasibility studies, genetic optimization, cultivation optimization, fed-batch optimization, and delivery of research cell bank with full documentation. Can include profit-sharing/risk-sharing models.
- Technology Licensing: After strain development, strains transferred under license agreement with proprietary rights to customer for use in manufacturing. Customers receive exclusive license to use developed strains for intended purposes.
- Patent Licensing: Patent applications claiming use of Vectron technologies for production of customer proteins may be part of project deliverables, providing customers with additional IP protection.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Feasibility Study (WP01) |
| Other | Multi-year contract | Full Strain Development Project |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels8 records
Vectron Biosolutions product offering
Product offeringCore offering
Vectron Biosolutions develops tailor-made E. coli expression vector technologies and provides bespoke bacterial strain development services for recombinant protein production. The company delivers engineered production strains and research cell banks to pharmaceutical, biomanufacturing, and industrial enzyme customers, leveraging three proprietary technology platforms (VB Expression, VB Evolution, VB Secretion) under multi-phase project engagements that typically conclude with licensing of the developed strain to the customer.
Product overview
Vectron Biosolutions offers a technology platform for microbial protein production, consisting of three core proprietary technologies: VB Expression (modular expression vector platform combining expression elements), VB Evolution (directed evolution approach creating novel vectors), and VB Secretion (microbial secretion technology). Supporting technologies include VB Expert, VB Solutions, and CYT Tags. The company provides strain development services including feasibility studies, genetic optimization, cultivation optimization, and research cell bank creation. In 2024, they expanded services to include enzyme evolution, fermentation scale-up, upstream process characterization, purification, and protein analysis services.
Differentiator
Problem solved
Functional benefit
Products and services
- Tailor-Made Strain Development Services Bespoke bacterial strain development service that engineers unique E. coli production strains optimized for each customer's specific protein, delivering maximal titers of biologically active, soluble protein. Projects follow up to 5 work packages and result in research cell bank delivery under license with proprietary rights to the customer.
- Feasibility Studies Initial screening and assessment service (WP01) evaluating plasmid copy number, signal peptides, fusion partners, expression strength, and chaperones to determine the optimal approach for producing a customer's target protein and whether to proceed with a full strain development project.
- Fermentation Services Scale-up service progressing engineered strains from bench to pilot scale under industrially relevant high cell density cultivation conditions, including fed-batch optimization. Processes frequently yield 10-60 g/L.
- Enzyme Evolution and Screening Service evaluating evolved enzyme activity and characterizing new variants to identify improved enzymatic processes for industrial and specialty enzyme customers.
- Protein Analysis Services Comprehensive product quality assessment including intact mass, glycan and disulfide bond profiling, in-vitro characterization, activity, binding affinity, and titer determination for customer proteins.
- Upstream Process Characterization Service supporting characterization of upstream fermentation processes for customer protein production, complementing strain development and fermentation services.
- Purification and Protein Quality Assessment Downstream processing service supporting purification of customer proteins from engineered E. coli strains, complementing upstream strain development and fermentation services.
Quantifiable outcome
- Record titers >60 g/L for E. coli produced proteins
- +6 more outcomes
Companies that use Vectron Biosolutions
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles4 records
Vectron Biosolutions technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Vectron Biosolutions partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and secondary.
- Cytovance BiologicscoreStrategic international collaboration to integrate Vectron's E. coli strain development services with Cytovance's microbial CDMO manufacturing capabilities. Enables customers to access complete package from gene to product for US market. Vectron brings next-generation vector engineering technologies while Cytovance provides cGMP manufacturing capacity including 1000L fermenters.
- Motif FoodWorkscorePartnership to develop next-generation animal-free proteins through precision fermentation. Vectron provides strain development expertise and proprietary expression technologies. Motif uses these for food technology applications including HEMAMI dairy alternatives and APPETEX texture enhancers. Expanded from existing 2-year collaboration.
- Sartorius Korea Biotech Co.coreExclusive distribution agreement making Sartorius Korea the exclusive agent for Vectron products and services in Republic of Korea. Provides Korean biotech and pharma companies easier access to Vectron's next-generation technologies for recombinant protein production.
- Mycenax Biotech Inc.secondaryNon-exclusive collaboration offering superior complete solution for microbial production of therapeutic proteins. Combines Vectron's state-of-the-art strain development with Mycenax's cost-efficient manufacture from experienced CMO with great track record.
- ArcticZymessecondaryNon-exclusive license agreement for recombinant expression of enzymes. Collaboration on two projects showed high success rate on large set of target enzymes in discovery pipeline and high yields in scaled-up production.
- EnginZymesecondaryLicense agreement for commercial rights to use Vectron's expression vector technology platform for manufacture of Candida antarctica CalB enzyme for biocatalysis applications. Includes right to combine with EnginZyme's proprietary EziG immobilization matrix.
- Scarab GenomicssecondaryPartnership to engineer genetically stable E. coli strains optimized for perfusion fermentation. Scarab's early results show protein production sustained for nearly 60 days - approximately 20 times longer than typical E. coli strains. Combining with VB Secretion technology for extended fermentation processes.
- SINTEFsecondaryResearch partner for Fab therapeutic protein production project funded by Norwegian Research Council. SINTEF contributes extensive experience with fed-batch fermentation to help develop Fab production processes targeting >10 g/L soluble Fabs.
Scale indicators9 records
Recent moves7 records
Expansion highlights6 records
Vectron Biosolutions competitors and assessment
Company assessmentDirect peers
- ATUM: ATUM (formerly DNA2.0) provides proprietary expression vectors and microbial protein production services; directly comparable as a strain-engineering / protein-expression CRO with comparable target customers.
- Cube Biotech: Cube Biotech offers expression systems and services for protein production in E. coli and other hosts, including difficult-to-express targets — directly overlapping with Vectron's tailor-made E. coli strain development offering.
- ProteoGenix: ProteoGenix is a CRO providing recombinant protein expression and production services across hosts including E. coli; comparable customer base of biotech and pharma developers needing custom strain or construct work.
- Cytovance Biologics: Cytovance is a microbial CDMO partnered with Vectron; comparable as a downstream microbial manufacturing provider and a partner that competes for similar strain-development-and-manufacturing opportunities.
- Scarab Genomics: Scarab engineers stabilized E. coli strains and partners with Vectron on perfusion fermentation; comparable as a specialized E. coli engineering company serving similar difficult-protein production applications.
Emerging players
- Bota Bio: Bota Bio is a synthetic biology / microbial biomanufacturing platform building engineered strains for industrial and specialty applications; comparable as a venture-backed microbial strain development platform, though broader in scope.
Broad incumbents
- Codexis: Codexis engineers enzymes and proteins for pharmaceutical and industrial applications using directed evolution (CodeEvolver) — directly comparable technology overlap with Vectron's VB Evolution directed-evolution platform.
- Ginkgo Bioworks: Ginkgo operates a much broader synthetic biology platform including cell engineering and protein production programs; comparable as a large-scale microbial engineering incumbent competing for similar strain-development wallet share.
- Twist Bioscience: Twist provides synthetic DNA and antibody discovery/optimization services; adjacent to Vectron as an upstream provider enabling protein expression workflows, though broader and more diversified across life sciences.
- WuXi Biologics: WuXi Biologics is a global biologics CDMO with microbial and mammalian capabilities; relevant benchmark as a scaled incumbent serving the same pharma/biotech customers who might otherwise engage Vectron for strain development.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Vectron Biosolutions social profiles
Digital presenceVectron Biosolutions financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vectron Biosolutions leadership team
Management profileNumber of profiles
Profiles7 records
Vectron Biosolutions subsidiaries and ownership
Company hierarchySubsidiaries1 record
Vectron Biosolutions funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vectron Biosolutions M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vectron Biosolutions
What does Vectron Biosolutions do?
Vectron Biosolutions develops tailor-made E. coli expression vector technologies and provides bespoke bacterial strain development services for recombinant protein production. The company delivers engineered production strains and research cell banks to pharmaceutical, biomanufacturing, and industrial enzyme customers, leveraging three proprietary technology platforms (VB Expression, VB Evolution, VB Secretion) under multi-phase project engagements that typically conclude with licensing of the developed strain to the customer.
Is Vectron Biosolutions a public or private company?
Vectron Biosolutions is a private company. It is classified as venture growth investor backed and is currently operating.
When was Vectron Biosolutions founded?
Vectron Biosolutions was founded in 2008. It employs 11 to 50 people.
Where is Vectron Biosolutions based?
Vectron Biosolutions is headquartered in Trondheim, Norway, in the Europe region.
How does Vectron Biosolutions make money?
Three revenue lines are on record. Strain Development Services are the primary driver. The others are technology Licensing and patent Licensing.
Who are Vectron Biosolutions's main competitors?
Direct peers on record are ATUM, Cube Biotech, ProteoGenix, Cytovance Biologics and Scarab Genomics. Bota Bio is listed as an emerging player. Broad incumbents are Codexis, Ginkgo Bioworks, Twist Bioscience and WuXi Biologics.
Does Vectron Biosolutions have an API?
No public API is recorded for Vectron Biosolutions.
What industry is Vectron Biosolutions in?
Vectron Biosolutions's product category is Microbial protein production services. Its primary akta.pro industry code is HLAAAJAF, Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 541714 and its SIC code is 8731.